Rostislav Raykov - Fennec Pharmaceuticals CEO, Director
| FENC Stock | USD 9.07 0.02 0.22% |
CEO
Mr. Rostislav Raykov is Chief Executive Officer, Director of the Company. He was Chairman of the Board of Adherex Technologies Inc. Mr. Raykov has served as a director of Adherex since July 2009 and as Chief Executive Officer since July 2009. Since May 2007, Mr. Raykov was a General Partner at DCML, a private investment partnership. Prior to DCML, from January 2006 to December 2007, Mr. Raykov was a portfolio manager for Alchem Investment Partners and John Levin Co Prior to founding Alchem, Mr. Raykov was a portfolio manager and securities analyst for John A. Levin Co. Event Driven Fund . Prior to joining John A. Levin Co., Mr. Raykov was a securities analyst for the Merger Fund at Tiedemann Investment Group and an investment banking analyst at Bear Stearns since 2015.
| Age | 48 |
| Tenure | 9 years |
| Address | 68 TW Alexander Drive, Research Triangle Park, NC, United States, 27709 |
| Phone | 919 636 4530 |
| Web | https://www.fennecpharma.com |
Fennec Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.2967) % which means that it has lost $0.2967 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.0559) %, meaning that it created substantial loss on money invested by shareholders. Fennec Pharmaceuticals' management efficiency ratios could be used to measure how well Fennec Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 1.48, whereas Return On Tangible Assets are forecasted to decline to (0.64). At present, Fennec Pharmaceuticals' Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Debt To Assets is expected to grow to 1.16, whereas Total Assets are forecasted to decline to about 16.1 M.Similar Executives
| Found 3 records | CEO Age | ||
| James Clark | LSI Industries | 53 | |
| Ronald Brown | LSI Industries | 63 | |
| Dennis Wells | LSI Industries | 55 | |
Management Performance
| Return On Equity | -10.06 | ||||
| Return On Asset | -0.3 |
Fennec Pharmaceuticals Leadership Team
Elected by the shareholders, the Fennec Pharmaceuticals' board of directors comprises two types of representatives: Fennec Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Fennec. The board's role is to monitor Fennec Pharmaceuticals' management team and ensure that shareholders' interests are well served. Fennec Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Fennec Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Chris Rallis, Independent Director | ||
| Rostislav Raykov, CEO, Director | ||
| Marco Brughera, Director | ||
| Mark Meier, VP Commercial | ||
| Khalid Islam, Chairman of the Board | ||
| Mark Gowland, Controller | ||
| Robert Andrade, Chief Officer | ||
| Lei Fang, President Inc | ||
| Anne McKay, Regulatory Consultant | ||
| Alexander MS, Consultant | ||
| Adrian Haigh, Independent Director | ||
| Steven Skolsky, Independent Director |
Fennec Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Fennec Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -10.06 | ||||
| Return On Asset | -0.3 | ||||
| Profit Margin | (0.76) % | ||||
| Operating Margin | (0.19) % | ||||
| Current Valuation | 264.02 M | ||||
| Shares Outstanding | 27.1 M | ||||
| Shares Owned By Insiders | 14.60 % | ||||
| Shares Owned By Institutions | 55.25 % | ||||
| Number Of Shares Shorted | 1.87 M | ||||
| Price To Earning | (3.82) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Fennec Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Fennec Pharmaceuticals' short interest history, or implied volatility extrapolated from Fennec Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fennec Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Fennec Stock refer to our How to Trade Fennec Stock guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Complementary Tools for Fennec Stock analysis
When running Fennec Pharmaceuticals' price analysis, check to measure Fennec Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fennec Pharmaceuticals is operating at the current time. Most of Fennec Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Fennec Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fennec Pharmaceuticals' price. Additionally, you may evaluate how the addition of Fennec Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |
Is Fennec Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fennec Pharmaceuticals. If investors know Fennec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fennec Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.60) | Revenue Per Share 0.8 | Quarterly Revenue Growth 5.342 | Return On Assets (0.30) | Return On Equity (10.06) |
The market value of Fennec Pharmaceuticals is measured differently than its book value, which is the value of Fennec that is recorded on the company's balance sheet. Investors also form their own opinion of Fennec Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Fennec Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fennec Pharmaceuticals' market value can be influenced by many factors that don't directly affect Fennec Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fennec Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fennec Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fennec Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.